Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting
The development of specific anti-cytokine/chemokine therapeutic strategies for atherosclerotic disease is challenging. Here, the authors have designed a peptide-based ectodomain mimic of the chemokine receptor CXCR4 that selectively targets MIF but not CXCL12 and blocks experimental atherosclerosis...
Guardado en:
Autores principales: | Christos Kontos, Omar El Bounkari, Christine Krammer, Dzmitry Sinitski, Kathleen Hille, Chunfang Zan, Guangyao Yan, Sijia Wang, Ying Gao, Markus Brandhofer, Remco T. A. Megens, Adrian Hoffmann, Jessica Pauli, Yaw Asare, Simona Gerra, Priscila Bourilhon, Lin Leng, Hans-Henning Eckstein, Wolfgang E. Kempf, Jaroslav Pelisek, Ozgun Gokce, Lars Maegdefessel, Richard Bucala, Martin Dichgans, Christian Weber, Aphrodite Kapurniotu, Jürgen Bernhagen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8d9c94b2adec4a06a56a819e022710e7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Emerging Strategies for the Management of Atherogenic Dyslipidaemia
por: Anandita Agarwala, et al.
Publicado: (2020) -
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
por: Alberto J Lorenzatti, et al.
Publicado: (2020) -
Hibernating brown bears are protected against atherogenic dyslipidemia
por: Sylvain Giroud, et al.
Publicado: (2021) -
Pathophysiological rationale for the results of atherogenic dyslipidemia simulation in rats
por: V. G. Banzaraksheev
Publicado: (2016) -
Modern principles of atherogenic dyslipidemia management in special groups of patients
por: Marina G. Bubnova, et al.
Publicado: (2020)